However, the in vivo antitumor effect of TRAIL is far from satisfactory, which has been predominantly attributed to the limited tumor uptake resulting from the poor tumor targeting as well as a short serum half-life of TRAIL 9. Here, TNFSF10 is linked to neoplasm.